Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If DD believes he has missed ARIA, it follows that he thinks the train has left the station and there is litle upside in chasing it.
I was probably guilty of a constructive sale years ago. It went through without a hitch.
A bit like wash sales which the IRS has never audited effectively, to my knowledge, until now. That may change with new reporting requirements for tax year 2011.
How will they remedy any damages if all domestic producers have driven out of business? Or will the exercise be to assess punitive damages?
Until December there'll be more beta than alpha in this stock, barring an unexpected 113 announcement.
Markets are mysterious, but I'd venture you made a good deal.
No real after market reaction. There's a piddling amount offered at 12 on ARCA, with a few shares traded at 12 at 16:27
Excellent question. I never have success wading through the apps jungle with an LG android phone, and a CC app would be very useful.
The DOJ is also involved. There may be a valid agenda, but it does seem Washington is toying with a nuclear button.
NEW YORK (Reuters) - Shares of U.S.-listed Chinese companies fell on Thursday after a top securities regulator said U.S. criminal authorities are investigating accounting irregularities at Chinese companies listed on U.S. stock exchanges.
Among companies that fell, Sohu.com Inc (NasdaqGS: SOHU - News) dropped 7.8 percent to $48.99, Baidu Inc (NasdaqGS: BIDU - News) lost 6 percent to $114, China Sky One Medical Inc (NasdaqGS: CSKI - News) declined 7.6 percent to $2.19, while Sina Corp (NasdaqGS: SINA - News) fell 8 percent to $74.60.
Thanks, now I see the volume.
What series are you referring to?
My first thought was that there might be rumors of a secondary, but this is now much much heavier than anything that could be accounted for by a secondary.
So, perhaps EXEL's niche for Cabo would be its appeal for men who want to kiss and have sex.
Men with advanced prostate cancer may typically be too old for that?
Merrill
Note: As of September 14, 2011 Alkermes (ALKS) is being removed from the US 1 list as part of a rebalancing but continues to be rated a BUY.
Please do not destroy the assumptions on which my personal war against ethanol fuel is based.
Should be a simple question - under current production methods is fuel ethanol produced from the biomass or the food part?
How do those numbers compare vs Pradaxa?
Boehringer claims
To go along with decreeing that fracking is now part of the SEC mandate (!).
This administration is blinded by its hatred (not too strong a word) of anything related to petroleum
Affluent consumers require greater choice than Carrefour's standard offerings can provide?
(I've never been in a Carrefour, please note.)
Not LOL, LOL. sob
Kindler -
Incredible.
NVS heard you berating the market for its stupidity and is now green for the day.
Good Swiss child, does what it's told.
CSCO
In a conference call following the earnings report, CEO John Chambers said the company sees a gradual improvement in the fiscal first quarter despite the fact that the environment for tech spending remains challenging. Growth in Asia and emerging markets is the strongest, he said.
This is a sobering part of the S&P release - and this is the base case, not the downside scenario.
Under our revised base case fiscal scenario–which we consider to be consistent with a ‘AA+’ long-term rating and a negative outlook–we now project that net general government debt would rise from an estimated 74% of GDP by the end of 2011 to 79% in 2015 and 85% by 2021. Even the projected 2015 ratio of sovereign indebtedness is high in relation to those of peer credits and, as noted, would continue to rise under the act’s revised policy settings
US FISCAL CONSOLIDATION PLAN FALLS SHORT OF WHAT WOULD BE NECESSARY TO STABILIZE DEBT DYNAMICS
You didn't know that until S&P told you what to think?
WSJ
By GORAN MIJUK
The U.K. health-care watchdog, in draft guidance, Friday recommended against reimbursing for Novartis AG's multiple-sclerosis medicine Gilenya because of uncertainties over the drug's clinical effectiveness for certain patients.
The move, which could deal a potential blow to the Swiss pharmaceutical giant's efforts to increase sales of the drug, drew fire from the U.K.'s Multiple Sclerosis Society, which said the regulator's assessment was disappointing.
Gilenya, which has been approved in the U.S., Europe and elsewhere, is one of Novartis's most promising medicines, expected to reach annual peak sales of more than $3 billion. The relatively high price for the pill—more than $40,000 per patient per year—has been considered justified because it is easier to use than standard treatments that require injections or infusions.
The U.K.'s National Institute for Health and Clinical Excellence, or NICE, while acknowledging that trial data showed that Gilenya benefits patients with highly active relapsing-remitting multiple sclerosis, said it was unclear how much the drug may help patients with other relapse forms.
NICE has rejected expensive drugs in the past, something analysts say is due to efforts to bring down health-care costs. Other countries such as Germany, Greece and Spain, have urged drug companies to curb prices. On average, austerity measures in Europe and the U.S. have shaved off more than 2% of drug sales in the first half of 2011, pharmaceutical companies have said.
"Unfortunately, our independent committee wasn't given sufficient evidence to show that Gilenya could reduce relapses considerably better than the other treatments," said Carole Longson, director of NICE's Health Technology Evaluation Center. "Based on the available clinical evidence and economic analysis, our independent committee concluded that Gilenya would not be effective good use of resources."
Novartis said it believes that Gilenya is a highly efficacious and cost-effective treatment for patients with multiple sclerosis and remains committed to engaging with NICE to ensure that patients will have access to the drug. Novartis in the past has offered alternative price plans to NICE.
NICE, whose independent committee will meet in October to review the consultation comments, said it expects to publish its final guidance on Gilenya in December. Until then, the drug will continue to be reimbursed, NICE said.
"This is disappointing news for people with multiple sclerosis," said Simon Gillespie, chief executive of the Multiple Sclerosis Society. "Access to treatments in the U.K. is very poor—in fact, people with multiple sclerosis would be better off living almost anywhere else in Europe." Around 100,000 people in the U.K. suffer from multiple sclerosis.
Write to Goran Mijuk at goran.mijuk@dowjones.com
From ElMat on SI (edit - this is a BP document, I forgot to note)
World energy growth over the next twenty years is expected to be dominated by emerging economies such as China, India, Russia and Brazil while improvements in energy efficiency measures are set to accelerate, according to BP’s latest projection of energy trends, the BP Energy Outlook 2030.
BP's 'base case' - or most likely projection - points to primary energy use growing by nearly 40% over the next twenty years, with 93% of the growth coming from non-OECD (Organisation of Economic Co-operation and Development) countries. Non-OECD countries are seen to rapidly increase their share of overall energy demand from just over half currently to two-thirds.
Over the same period, energy intensity, a key measure of energy use per unit of economic output, is set to improve globally led by rapid efficiency gains in the same non-OECD economies, under these projections <snip>
http://www.siliconinvestor.com/readmsg.aspx?msgid=27537751
Dew has informed me that the post was facetious but I was too dumb to see that - but he was gentle about it.
Sanofi-Aventis is having their drug reps take Silenor off the shelves
How do they pull that off? I must be misunderstanding.
They might have covered it up too for another 30 years but for the remarkable firestorm of criticism that developed on the Sina Weibo microblogging site.It seems to have totally escaped any attempt at censorship.
Thanks. I'd missed that.
http://uk.ibtimes.com/articles/20110722/hungary-destroys-all-monsanto-gmo-maize-fields.htm
In an effort to rid the country of Monsanto's GMO products Hungary has stepped up the pace. This looks like its going to be another slap in the face for Monsanto. A new regulation was introduced this March which stipulates that seeds are supposed to be checked for GMO before they are introduced to the market. Unfortunately, some GMO seeds made it to the farmers without them knowing it.
Almost 1000 acres of maize found to have been grown with genetically modified seeds have been destroyed throughout Hungary deputy state secretary of the Ministry of Rural Development Lajos Bognar said. The GMO maize has been ploughed under, said Lajos Bognar, but pollen has not spread from the maize, he added.
Unlike several EU members, GMO seeds are banned in Hungary. The checks will continue despite the fact that seed traders are obliged to make sure that their products are GMO free, Bognar said.
During their investigation, controllers have found Pioneer and Monsanto products among the seeds planted.
The free movement of goods within the EU means that authorities will not investigate how the seeds arrived in Hungary but they will check where the goods can be found, Bognar said. Regional public radio reported that the two biggest international seed producing companies are affected in the matter and GMO seeds could have been sown on up to thousands of hectares in the country.
Most of the local farmers have complained since they just discovered they were using GMO seeds. With season already under way, it is too late to sow new seeds, so this years harvest has been lost.
And to make things even worse for the farmers, the company that distributed the seeds in Baranya county is under liquidation. Therefore, if any compensation is paid by the international seed producers, the money will be paid primarily to that company's creditors, rather than the farmers.
And today may be a good day to have added some DE.
Is ABT more exposed to emerging markets than most other large pharmas, do you know?
At least one of the brokers I use will not accept market orders in the pre or post market.
As the WSJ article posted by Dew makes clear, the Canadians are over a barrel - the line to Cushing is beset by opposition on the U.S. side, and I haven't seen any indication that opposition within B.C. from either the general public or the First Nation (what a euphemism) bands is subsiding. The latter may be a matter of money, but I haven't seen any indication that active negotiations are under way, tho common sense suggests they must be.
It's seems that the market has come round to iwfal's skeptical view of the significance of XL 184's effects on bone lesions. Would have saved me some money if I'd listened more attentively.
yes, that was stupid of me. Thanks to you and Oakes.
Beats me, but it may have something to do with sulfur as a byproduct of sour crude refining.
I copied that because I thought that such a useful sounding drug would be a meaningful contributor to PFE revenue. Turns out it's fiddlesticks, even with the vast legions of smokers in East Asia. Missing an opportunity, or, more likely lack of local government support for a program that could cut into revenues?